Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

UK Scientists Pioneer World’s First Blood Test for Brain Cancer

NextEdge Admin

31 Dec 2023

2 min 25 sec

A groundbreaking clinical validation study led by Imperial College Healthcare NHS Trust and Imperial College London suggests that a simple blood test could revolutionize the diagnosis of the deadliest form of brain cancer, glioblastoma (GBM). The technique, proven effective for glial tumors, including GBM, could eliminate the need for invasive and high-risk surgical biopsies, leading to earlier diagnoses, faster treatments, and potentially increased survival rates.

The world-first TriNetra-Glio blood test, developed by Datar Cancer Genetics and validated in the Brain Tumour Research Centre of Excellence, isolates circulating tumor cells in the blood. These cells can be analyzed with the same cellular detail as traditional tissue samples, providing a non-invasive and cost-effective diagnostic solution. The FDA has shown interest, raising hopes for a larger UK study that, if successful, could benefit patients within two years.

The technology is particularly crucial for fast-growing and aggressive cases where surgical biopsies are challenging. The blood test could be a game-changer for patients with inaccessible tumors due to location or other constraints.

Less than 1% of GBM patients live for over 10 years, with a prognosis as short as 12 months for many. The study’s findings are significant, as brain tumors are the leading cause of cancer-related deaths in individuals under 40. Brain Tumour Research emphasizes the urgent need for novel approaches and increased funding, urging the government and larger charities to invest more in research for improved treatments and, ultimately, a cure for this devastating disease.